Treatment of natalizumab‐associated PML with filgrastim
Abstract Objective There is no consensus on the treatment of progressive multifocal leukoencephalopathy (PML) occurring in multiple sclerosis (MS) patients treated with natalizumab (Nz). We report novel immune activating treatment with filgrastim of Nz‐associated PML in MS patients treated at Rush U...
Main Authors: | Dusan Stefoski, Roumen Balabanov, Rasha Waheed, Michael Ko, Igor J. Koralnik, Fabian Sierra Morales |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-05-01
|
Series: | Annals of Clinical and Translational Neurology |
Online Access: | https://doi.org/10.1002/acn3.776 |
Similar Items
-
Improving risk‐stratification of natalizumab‐associated PML
by: Bastian Tugemann, et al.
Published: (2021-03-01) -
Pathologic Findings of Chronic PML-IRIS in a Patient with Prolonged PML Survival Following Natalizumab Treatment
by: Mai Himedan MD, et al.
Published: (2017-09-01) -
Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities
by: Justin M. Honce, et al.
Published: (2015-01-01) -
PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
by: J. Killestein, et al.
Published: (2014-01-01) -
Immunological markers for PML prediction in MS patients treated with natalizumab
by: Caroline eAntoniol, et al.
Published: (2015-01-01)